Rocket Pharmaceuticals Inc to Discuss Danon Program Call Transcript
Welcome to the company update on Danon trial conference call. My name is Vanessa, and I will be your operator for today. (Operator Instructions).
I will now turn the call over to your host, Claudine Prowse, Senior Vice President of Strategy and Corporate Development.
Thanks, Vanessa. Good afternoon, and thank you all for joining us. The purpose of this call is to share an important update on our Danon disease Phase I clinical trial as discussed this morning with the FDA and disclosed in today's first quarter 2021 financial results press release.
Before we begin, I'd like to remind you that various remarks we will make today constitute forward-looking statements that are qualified by cautionary statements. Please refer to our SEC filings if you have any questions.
Participating on today's call are Dr. Gaurav Shah, Chief Executive Officer; Kinnari Patel, President and Chief Operating Officer; Dr. Jonathan Schwartz, Chief
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |